Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 2

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

NCT ID: NCT02693535Sponsor: American Society of Clinical OncologyLast updated: 2026-05-29

Summary

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Detailed description

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.

Arms & interventions

  • DrugPalbociclib

    drug

  • DrugSunitinib

    drug

  • DrugTemsirolimus

    drug

  • DrugTrastuzumab and Pertuzumab

    drug

  • DrugVemurafenib and Cobimetinib

    drug

  • DrugRegorafenib

    drug

  • DrugOlaparib

    drug

  • DrugNivolumab and Ipilimumab

    drug

  • DrugAbemaciclib

    drug

  • DrugTalazoparib

    drug

  • DrugAtezolizumab and Talazoparib

    drug

  • DrugTucatinib plus Trastuzumab Subcutaneous (SC)

    drug

  • DrugFutibatinib

    drug

  • DrugDabrafenib plus Trametinib

    Drug

  • DrugFam-Trastuzumab Deruxtecan-Nxki (TDxD)

    Drug

Outcome measures

Primary

  • Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria

    Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used.

    Time frame: Assessed at 16 weeks of treatment

Secondary

  • Overall survival (OS)

    Time frame: Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years

Eligibility criteria

Sex: AllAge: 12 Years and olderHealthy volunteers: No
Inclusion Criteria: * 12 years of age or older (\*Restrictions apply. Not all therapies are available for patients \<18) * Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated * Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria) * Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria: 1. Absolute neutrophil count ≥ 1.5 x 106/µl 2. Hemoglobin \> 9.0 g/dl 3. Platelets \> 75,000/µl 4. Total bilirubin \< 2.0 mg/ dl, except in patients with Gilbert's Syndrome 5. Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) \< 2.5 x institutional upper limit of normal (ULN) (or \< 5 x ULN in patients with known hepatic metastases) 6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2 * Patients must have disease that can be objectively measured by physical or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or a subcutaneous or superficial lesion that can be measured with calipers by clinical exam. For lymph nodes, the short axis must be ≥15 mm. Patient's whose disease cannot be objectively measured by physical or radiographic examination (e.g., elevated serum tumor marker only, bone-only disease without an identifiable soft tissue component, or patients with only assessable non-measurable disease) are NOT eligible. * Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above. * Ability to understand and the willingness to sign a written informed consent/assent document. * Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol. * For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome. * Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study drug, or completely abstain from sexual intercourse. Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1. Exclusion Criteria: * Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible * Patients with primary brain tumors or new, untreated or progressive leptomeningeal metastases are excluded * Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 3 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment. * Patients with known progressive brain metastases are eligible but additional eligibility criteria apply. Note: there are additional exclusion criteria that may apply

Study locations (174)

University of Alabama at Birmingham Comprehensive Cancer Center

Birmingham, Alabama, 35294

Recruiting
Kun Yuan · Contact
205-644-2584kunyuan@uabmc.edu
Mehmet Akce, MD · Principal Investigator

Cancer Treatment Centers of America-Phoenix

Phoenix, Arizona, 85338

Recruiting
Alex Lizzul · Contact
602-872-5654alizzul@coh.org
Sagun Shrestha, MD · Principal Investigator

Sutter Auburn

Auburn, California, 95602

Recruiting
Kirsten Babski · Contact
916-878-4990BabskiK@sutterhealth.org
Nitin Rohatgi, MD · Principal Investigator

Sutter Alta Bates

Berkeley, California, 94705

Recruiting
Christopher Tang · Contact
510-204-3428Christopher.Tang@sutterhealth.org
Nitin Rohatgi, MD · Principal Investigator

The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate

Los Angeles, California, 90025

Recruiting
Teri Mata · Contact
310-231-2115tmata@theangelesclinic.org
Omid Hamid, MD · Principal Investigator

Kaiser Permanente - Oakland Medical Center

Oakland, California, 94611

Recruiting
Desiree Goldstein · Contact
desiree.goldstein@kp.org
Jennifer M Suga, MD · Principal Investigator

Sutter Palo Alto Medical Foundation: Palo Alto

Palo Alto, California, 94301

Recruiting
· Contact
clinicaltrials@pamf.org

Kaiser Permanente - Roseville Medical Center

Roseville, California, 95661

Recruiting
Desiree Goldstein · Contact
desiree.goldstein@kp.org
Jennifer M Suga, MD · Principal Investigator

Sutter Roseville

Roseville, California, 95661

Recruiting
Kirsten Babski · Contact
916-878-4990BabskiK@sutterhealth.org
Nitin Rohatgi, MD · Principal Investigator

Kaiser Permanente - Sacramento Medical Center

Sacramento, California, 95814

Recruiting
Desiree Goldstein · Contact
desiree.goldstein@kp.org
Jennifer M Suga, MD · Principal Investigator

Sutter Sacramento

Sacramento, California, 95816

Recruiting
· Contact
SIMR@sutterhealth.org
Nitin Rohatgi, MD · Principal Investigator

Kaiser Permanente - South San Francisco Medical Center

San Francisco, California, 94080

Recruiting
Desiree Goldstein · Contact
desiree.goldstein@kp.org
Jennifer M Suga, MD · Principal Investigator

California Pacific Medical Center Research Institute

San Francisco, California, 94115

Recruiting
· Contact
415-600-1654clinicalresearch@sutterhealth.org
Nitin Rohatgi, MD · Principal Investigator

Kaiser Permanente - San Francisco Medical Center

San Francisco, California, 94115

Recruiting
Desiree Goldstein · Contact
desiree.goldstein@kp.org
Jennifer M Suga, MD · Principal Investigator

Sutter Cancer Research Consortium

San Francisco, California, 94115

Recruiting
Laurel Brechtel · Contact
415-600-1654BrechtLa@cpmcri.org
Stacy D'Andre, MD · Principal Investigator

Kaiser Permanente - San Jose Medical Center

San Jose, California, 95119

Recruiting
Desiree Goldstein · Contact
desiree.goldstein@kp.org
Jennifer M Suga, MD · Principal Investigator

Kaiser Permanente - San Leandro Medical Center

San Leandro, California, 94577

Recruiting
Desiree Goldstein · Contact
desiree.goldstein@kp.org
Jennifer M Suga, MD · Principal Investigator

Sutter Sansum Clinic

Santa Barbara, California, 93105

Recruiting
Selina Perez · Contact
831-458-5837Selina.Perez@sutterhealth.org
Nitin Rohatgi, MD · Principal Investigator

Kaiser Permanente - Santa Clara Medical Center

Santa Clara, California, 95051

Recruiting
Desiree Goldstein · Contact
desiree.goldstein@kp.org
Jennifer M Suga, MD · Principal Investigator

Sutter Palo Alto Medical Foundation: Santa Cruz

Santa Cruz, California, 95065

Recruiting
· Contact
clinicaltrials@pamf.org

Sutter Palo Alto Medical Foundation: Fremont

Santa Cruz, California, 994538

Recruiting
· Contact
clinicaltrials@pamf.org

Sutter Palo Alto Medical Foundation: Sunnyvale

Sunnyvale, California, 94086

Recruiting
· Contact
clinicaltrials@pamf.org

Kaiser Permanente - Vallejo Medical Center

Vallejo, California, 94589

Recruiting
Desiree Goldstein · Contact
desiree.goldstein@kp.org
Jennifer M. Suga, MD · Principal Investigator

Kaiser Permanente - Walnut Creek Medical Center

Walnut Creek, California, 94596

Recruiting
Desiree Goldstein · Contact
desiree.goldstein@kp.org
Jennifer M Suga, MD · Principal Investigator

Saint Vincent's Medical Center (SVMC)

Bridgeport, Connecticut, 06606

Recruiting
· Contact
860-972-4700CancerResearchSupport@hhchealth.org
Wylie Hosmer, MD · Principal Investigator

Hartford Hospital

Hartford, Connecticut, 06102

Recruiting
· Contact
860-972-4700CancerResearchSupport@hhchealth.org
Wylie Hosmer, MD · Principal Investigator

Midstate Medical Center (MSMC)

Meriden, Connecticut, 06451

Recruiting
· Contact
860-972-4700CancerResearchSupport@hhchealth.org
Wylie Hosmer, MD · Principal Investigator

The Hospital of Central Connecticut (HOCC) Cancer Center

New Britain, Connecticut, 06053

Recruiting
· Contact
860-972-4700CancerResearchSupport@hhchealth.org
Wylie Hosmer, MD · Principal Investigator

William W. Backus Hospital

Norwich, Connecticut, 06360

Recruiting
· Contact
860-972-4700CancerResearchSupport@hhchealth.org
Wylie Hosmer, MD · Principal Investigator

Charlotte Hungerford

Torrington, Connecticut, 06790

Recruiting
· Contact
860-972-4700CancerResearchSupport@hhchealth.org
Wylie Hosmer, MD · Principal Investigator

Windham Hospital (WH)

Willimantic, Connecticut, 06226

Recruiting
· Contact
860-972-4700CancerResearchSupport@hhchealth.org
Wylie Hosmer, MD · Principal Investigator

Florida Cancer Specialists North / Sarah Cannon Research Institute

Altamonte Springs, Florida, 32701

Active Not Recruiting

University of Miami/Sylvester Cancer Institute - Aventura

Aventura, Florida, 33180

Recruiting
Carolina Troche, BS · Contact
305-243-1481cxt582@med.miami.edu
Carmen Calfa, MD · Principal Investigator

Florida Cancer Specialists South / Sarah Cannon Research Institute

Bonita Springs, Florida, 34135

Active Not Recruiting

Florida Cancer Specialists South / Sarah Cannon Research Institute

Bradenton, Florida, 34211

Active Not Recruiting

Florida Cancer Specialists North / Sarah Cannon Research Institute

Brandon, Florida, 33511

Active Not Recruiting

Florida Cancer Specialists South / Sarah Cannon Research Institute

Cape Coral, Florida, 33909

Active Not Recruiting

Florida Cancer Specialists North / Sarah Cannon Research Institute

Clearwater, Florida, 33761

Active Not Recruiting

University of Miami/Sylvester Cancer Institute - Lennar

Coral Gables, Florida, 33146

Recruiting
Carolina Troche, BS · Contact
305-243-1481cxt582@med.miami.edu
Carmen Calfa, MD · Principal Investigator

University of Miami/Sylvester Cancer Institute - Deerfield Beach

Deerfield Beach, Florida, 33442

Recruiting
Carolina Troche, BS · Contact
305-243-1481cxt582@med.miami.edu
Carmen Calfa, MD · Principal Investigator

Holy Cross Hospital

Fort Lauderdale, Florida, 33308

Recruiting
· Contact
734-712-3671MCRCwebsitecontactform@trinity-health.org
Zdenka Segota, MD · Principal Investigator

Florida Cancer Specialists South / Sarah Cannon Research Institute

Fort Myers, Florida, 33901

Active Not Recruiting

Florida Cancer Specialists South / Sarah Cannon Research Institute

Fort Myers, Florida, 33905

Active Not Recruiting

Florida Cancer Specialists South / Sarah Cannon Research Institute

Fort Myers, Florida, 33908

Active Not Recruiting

Florida Cancer Specialists North / Sarah Cannon Research Institute

Gainesville, Florida, 32605

Active Not Recruiting

University of Florida Health

Gainesville, Florida, 32610

Recruiting
Anna Kukulka, RN, BSN · Contact
352-293-2551akukulka@ufl.edu
Thomas George, MD · Principal Investigator

Florida Cancer Specialists North / Sarah Cannon Research Institute

Largo, Florida, 33770

Active Not Recruiting

Florida Cancer Specialists North / Sarah Cannon Research Institute

Lecanto, Florida, 34461

Active Not Recruiting

University of Miami Sylvester Comprehensive Cancer Center

Miami, Florida, 33136

Recruiting
Carolina Troche, BS · Contact
305-243-1481cxt582@med.miami.edu
Carmen Calfa, MD · Principal Investigator

University of Miami/Sylvester Cancer Institute - Alex's Place

Miami, Florida, 33136

Recruiting
Carolina Troche, BS · Contact
305-243-1481cxt582@med.miami.edu
Carmen Calfa, MD · Principal Investigator

University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building

Miami, Florida, 33136

Recruiting
Carolina Troche, BS · Contact
305-243-1481cxt582@med.miami.edu
Carmen Calfa, MD · Principal Investigator

University of Miami/Sylvester Cancer Institute - Kendall

Miami, Florida, 33176

Recruiting
Carolina Troche, BS · Contact
305-243-1481cxt582@med.miami.edu
Carmen Calfa, MD · Principal Investigator

University of Miami/Sylvester Cancer Institute - Sole Mia

Miami, Florida, 33181

Recruiting
Carolina Troche, BS · Contact
305-243-1481cxt582@med.miami.edu
Carmen Calfa, MD · Principal Investigator

Florida Cancer Specialists South / Sarah Cannon Research Institute

Naples, Florida, 34102

Active Not Recruiting

Florida Cancer Specialists North / Sarah Cannon Research Institute

Ocala, Florida, 34474

Active Not Recruiting

Florida Cancer Specialists North / Sarah Cannon Research Institute

Orange City, Florida, 32763

Active Not Recruiting

Florida Cancer Specialists North / Sarah Cannon Research Institute

Orlando, Florida, 32806

Active Not Recruiting

University of Miami/Sylvester Cancer Institute - Plantation

Plantation, Florida, 33324

Recruiting
Carolina Troche, BS · Contact
305-243-1481cxt582@med.miami.edu
Carmen Calfa, MD · Principal Investigator

Florida Cancer Specialists South / Sarah Cannon Research Institute

Port Charlotte, Florida, 33980

Active Not Recruiting

Florida Cancer Specialists South / Sarah Cannon Research Institute

Sarasota, Florida, 34232

Active Not Recruiting

Florida Cancer Specialists South / Sarah Cannon Research Institute

Sarasota, Florida, 34236

Active Not Recruiting

Florida Cancer Specialists North / Sarah Cannon Research Institute

St. Petersburg, Florida, 33701

Active Not Recruiting

Florida Cancer Specialists North / Sarah Cannon Research Institute

Tampa, Florida, 33607

Active Not Recruiting

Florida Cancer Specialists North / Sarah Cannon Research Institute

Tavares, Florida, 32778

Active Not Recruiting

Florida Cancer Specialists North / Sarah Cannon Research Institute

The Villages, Florida, 32159

Active Not Recruiting

Florida Cancer Specialists North / Sarah Cannon Research Institute

Trinity, Florida, 34655

Active Not Recruiting

Florida Cancer Specialists South / Sarah Cannon Research Institute

Venice, Florida, 34285

Active Not Recruiting

Florida Cancer Specialists South / Sarah Cannon Research Institute

Venice, Florida, 34292

Active Not Recruiting

Florida Cancer Specialists North / Sarah Cannon Research Institute

Winter Park, Florida, 32789

Active Not Recruiting

Cancer Treatment Centers of America - Atlanta

Atlanta, Georgia, 30265

Recruiting
Elizabeth McKoy, RN, BSN · Contact
770-400-7177emckoy@coh.org
Bamidele Adesunloye, MD · Principal Investigator

Emory University Winship Cancer Institute

Atlanta, Georgia, 30322

Recruiting
Krystal Bagley · Contact
404-778-8670krystal.joi.bagley@emory.edu
Olatunji Alese, MD · Principal Investigator

Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion

Savannah, Georgia, 31405

Recruiting
Stephanie Smith, RN, MSN, OCN · Contact
912-819-5723smiths1@sjchs.org
Mark Taylor, MD · Principal Investigator

Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute

Savannah, Georgia, 31405

Recruiting
Stephanie Smith, RN, MSN, OCN · Contact
912-819-5723smiths1@sjchs.org
Mark Taylor, MD · Principal Investigator

Lewis Cancer & Research Pavilion

Savannah, Georgia, 31405

Recruiting
Stephanie Smith, RN, MSN, OCN · Contact
912-819-5723smiths1@sjchs.org
Mark Taylor, MD · Principal Investigator

Summit Cancer Care

Savannah, Georgia, 31405

Recruiting
Stephanie Smith, RN, MSN, OCN · Contact
912-819-5723smiths1@sjchs.org
Mark Taylor, MD · Principal Investigator

The Queen's Medical Center - POB I

Honolulu, Hawaii, 96813

Recruiting
Tim Kelleher · Contact
808-691-8582tkelleher@queens.org
Jared Acoba, MD · Principal Investigator

The Queen's Medical Center - Punchbowl

Honolulu, Hawaii, 96813

Recruiting
Tim Kelleher · Contact
808-691-8582tkelleher@queens.org
Jared Acoba, MD · Principal Investigator

The Queen's Medical Center - Kuakini

Honolulu, Hawaii, 96817

Recruiting
Tim Kelleher · Contact
808-691-8582tkelleher@queens.org
Jared Acoba, MD · Principal Investigator

The Queen's Medical Center - West Oahu

‘Ewa Beach, Hawaii, 96706

Recruiting
Tim Kelleher · Contact
808-691-8582tkelleher@queens.org
Jared Acoba, MD · Principal Investigator

Cancer Treatment Centers of America-Chicago

Chicago, Illinois, 60099

Recruiting
Office of Clinical Trials · Contact
847-731-1777CHIResearch@coh.org
Evan Pisick, MD · Principal Investigator

Community Health Network (The University of Texas MD Anderson Cancer Center)

Indianapolis, Indiana, 46250

Recruiting
Kshipra Sharma, MPH, MS · Contact
713-745-8431Ksharma2@MDAnderson.org
Funda Meric-Bernstam, MD · Principal Investigator

Harold Alfond Center for Cancer Care

Augusta, Maine, 04330

Recruiting
Sandra Neptune, BSN, RN · Contact
207-626-4811sandra.neptune@mainegeneral.org
Lindsay Hathaway, MD · Principal Investigator

Jackson Laboratory - Maine Cancer Genomics Initiative

Augusta, Maine, 04330

Recruiting
Petra Helbig, CCRP · Contact
207-664-4659Petra.Helbig@jax.org
Jens Rueter, MD · Principal Investigator

Waldo County General Hospital

Belfast, Maine, 04915

Recruiting
Jen Dalton, MHA, BSN, RN · Contact
207-294-8291JDalton@mmc.org
Roger Inhorn, MD · Principal Investigator

SMHC Cancer Care and Blood Disorders -Biddeford

Biddeford, Maine, 04005

Recruiting
Jen Dalton · Contact
207-294-8291JDalton@mmc.org
Roger Inhorn, MD · Principal Investigator

Northern Light Cancer Care

Brewer, Maine, 04412

Recruiting
Carla Mancini, MHA, BSN, RN · Contact
207-973-5581cmancini@northernlight.org
Sarah Sinclair, MD · Principal Investigator

Raish Peavey Haskell Children's Cancer and Treatment Center

Brewer, Maine, 04412

Recruiting
Carla C Mancini, RN, BSN, OCN · Contact
207-973-5581cmancini@northernlight.org
Sarah Sinclair, MD · Principal Investigator

MaineHealth Cancer Care -Brunswick

Brunswick, Maine, 04011

Recruiting
Jen Dalton, MHA, BSN, RN · Contact
207-294-8291JDalton@mmc.org
Roger Inhorn, MD · Principal Investigator

New England Cancer Specialist

Kennebunk, Maine, 04043

Recruiting
Patricia C Collins · Contact
207-303-3422collip@newecs.org
Christian Thomas, MD · Principal Investigator

York Hopsital Oncology & Infusion Care in Kittery

Kittery, Maine, 03904

Recruiting
Brenda i Kiberd, RN · Contact
207-361-6115Brenda.Kiberd@yorkhospital.com
Marilyn McLaughlin, MD · Principal Investigator

Stephens Memorial Hospital

Norway, Maine, 04268

Recruiting
Jen Dalton, MHA, BSN, RN · Contact
207-294-8291JDalton@mmc.org
Roger Inhorn, MD · Principal Investigator

Penobscot Bay Medical Center

Rockport, Maine, 04856

Recruiting
Jen Dalton, MHA, BSN, RN · Contact
207-294-8291JDalton@mmc.org
Roger Inhorn, MD · Principal Investigator

SMHC Cancer Care and Blood Disorders -Sandford

Sanford, Maine, 04073

Recruiting
Jen Dalton, MHA, BSN, RN · Contact
207-294-8291JDalton@mmc.org
Roger Inhorn, MD · Principal Investigator

Maine Children's Cancer Program

Scarborough, Maine, 04074

Recruiting
Jen Dalton, MHA, BSN, RN · Contact
207-294-8291JDalton@mmc.org
Roger Inhorn, MD · Principal Investigator

Maine Medical Partner's Women's Health

Scarborough, Maine, 04074

Recruiting
Jen Dalton, MHA, BSN, RN · Contact
207-294-8291JDalton@mmc.org
Roger Inhorn, MD · Principal Investigator

New England Cancer Specialist

Scarborough, Maine, 04074

Recruiting
Patricia Collins, BA, CCRC · Contact
207-303-3422collip@newecs.org
Christian Thomas, MD · Principal Investigator

MaineHealth Cancer Care -South Portland

South Portland, Maine, 04106

Recruiting
Jen Dalton, MHA, BSN, RN · Contact
207-294-8291JDalton@mmc.org
Roger Inhorn, MD · Principal Investigator

New England Cancer Specialist

Topsham, Maine, 04086

Recruiting
Patricia C Collins, BA, CCRC · Contact
207-303-3422collip@newecs.org
Christian Thomas, MD · Principal Investigator

York Hospital Oncology & Infusion Care in Wells

Wells, Maine, 04090

Recruiting
Brenda Kiberd, RN · Contact
207-361-6115Brenda.Kiberd@yorkhospital.com
Marilyn McLaughlin, MD · Principal Investigator

York Hospital Oncology & Infusion Care in York

York Village, Maine, 03909

Recruiting
Brenda i Kiberd, RN · Contact
207-361-6115Brenda.Kiberd@yorkhospital.com
Marilyn McLaughlin, MD · Principal Investigator

Trinity Health Ann Arbor Hospital

Ann Arbor, Michigan, 48106

Recruiting
· Contact
734-712-3671MCRCwebsitecontactform@trinity-health.org
Elie Dib, MD · Principal Investigator

University of Michigan

Ann Arbor, Michigan, 48109

Active Not Recruiting

Henry Ford Health Saint John Hospital

Detroit, Michigan, 48236

Recruiting
· Contact
734-712-3671MCRCwebsitecontactform@trinity-health.org
Carrie Dul, MD · Principal Investigator

Genesys Hurley Cancer Institute

Flint, Michigan, 48503

Recruiting
· Contact
734-712-3671MCRCwebsitecontactform@trinity-health.org
Paul Adams, MD · Principal Investigator

Cancer Research Consortium of West Michigan

Grand Rapids, Michigan, 49503

Recruiting
Connie Szczepanek, RN · Contact
616-391-1230crcwm-regulatory@crcwm.org
Kathleen J. Yost, MD · Principal Investigator

University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912

Recruiting
· Contact
734-712-3671MCRCwebsitecontactform@trinity-health.org
Gordan Srkalovic, MD · Principal Investigator

Trinity Health Livonia Hospital

Livonia, Michigan, 48154

Recruiting
· Contact
734-712-7251MCRCwebsitecontactform@trinity-health.org
Amit Mohindra, MD · Principal Investigator

Trinity Health Oakland Hospital

Pontiac, Michigan, 48341

Recruiting
· Contact
734-712-3671MCRCwebsitecontactform@trinity-health.org
Julie Goodman, MD · Principal Investigator

MyMichigan Medical Center Saginaw

Saginaw, Michigan, 48601

Recruiting
· Contact
734-712-3671MCRCwebsitecontactform@trinity-health.org
Nicholas Damico, MD · Principal Investigator

Michigan Cancer Research Consortium

Traverse City, Michigan, 48341

Recruiting
Beth LaVasseur, RN, MS · Contact
734-712-7251Beth.LaVasseur@stjoeshealth.org
· Contact
877-590-5995
Philip Stella, MD · Principal Investigator

Henry Ford Health Warren Hospital

Warren, Michigan, 48093

Recruiting
· Contact
734-712-3671MCRCwebsitecontactform@trinity-health.org
Carrie Dul, MD · Principal Investigator

University of Nebraska Medical Center

Omaha, Nebraska, 68198

Recruiting
Micki Bethea, BS · Contact
402-559-8011mbethea@unmc.edu
Alissa Marr, MD · Principal Investigator

NH Oncology - Hematology, PA

Concord, New Hampshire, 03103

Recruiting
Ali Fleury · Contact
603-314-6888A.Fleury@nhoh.com
Michael Buff, MD · Principal Investigator

Solinsky Center for Cancer Care

Manchester, New Hampshire, 03103

Recruiting
Ali Fleury, BA, CCRP · Contact
603-314-6888A.Fleury@nhoh.com
Michael Buff, MD · Principal Investigator

New England Cancer Specialist

Portsmouth, New Hampshire, 03801

Recruiting
Patricia C Collins, BA, CCRC · Contact
207-303-3422collip@newecs.org
Christian Thomas, MD · Principal Investigator

Lovelace Medical Center - Saint Joseph Square

Albuquerque, New Mexico, 87102

Recruiting
Leslie Byatt · Contact
505-925-0366lpbyatt@salud.unm.edu
Bernard Tawfik, MD · Principal Investigator

Presbyterian Kaseman Hospital

Albuquerque, New Mexico, 87110

Recruiting
Monique Robertson, RN · Contact
505-559-6100mrobertso2@phs.org
Bernard Tawfik, MD · Principal Investigator

The University of New Mexico Comprehensive Cancer Center

Albuquerque, New Mexico, 87131

Recruiting
Sheri Westgate, RN-BSN, OCN · Contact
505-925-0383swestgate@salud.unm.edu
Bernard Tawfik, MD · Principal Investigator

Memorial Medical Center

Las Cruces, New Mexico, 88011

Recruiting
Kim Hoffman, RN · Contact
575-556-6545kim.hoffman@lpnt.net
Bernard Tawfik, MD · Principal Investigator

Presbyterian Rust Medical Center

Rio Rancho, New Mexico, 87124

Recruiting
Andrea Yost · Contact
505-253-7878ayost3@phs.org
Bernard Tawfik, MD · Principal Investigator

Northwell Health Monter Cancer Center

Lake Success, New York, 11042

Recruiting
Mary Agnes Templeton · Contact
516-734-8979mtempleton@northwell.edu
Marina Frimer, MD · Principal Investigator

Northern Westchester Hospital

Mount Kisco, New York, 10549

Recruiting
Jemima Jacob, MPH · Contact
914-666-1366jjacob22@northwell.edu
Marina Frimer, MD · Principal Investigator

Cohen Children's Medical Center

New Hyde Park, New York, 11040

Recruiting
Shreya Seepersaud · Contact
718-470-7146sseepersaud2@northwell.edu
Marina Frimer, MD · Principal Investigator

Manhattan Eye, Ear, and Throat Hospital

New York, New York, 10065

Recruiting
Leila Nasr · Contact
lnasr@northwell.edu
Marina Frimer, MD · Principal Investigator

Staten Island University Hospital

New York, New York, 10305

Recruiting
Sammi Ruan · Contact
718-226-1489sruan2@northwell.edu
Melissa McCarthy · Contact
718-226-1805mccarthy22@northwell.edu
Marina Frimer, MD · Principal Investigator

Queens Cancer Center

Rego Park, New York, 11374

Recruiting
Harmandeep Kaur · Contact
718-412-0773hkaur37@northwell.edu
Marina Frimer, MD · Principal Investigator

Phelps Hospital

Sleepy Hollow, New York, 10591

Recruiting
Barbara Turner, RN · Contact
914-269-1949Bturner1@northwell.edu
Shyrley Gomez · Contact
Sgomez21@northwell.edu
Marina Frimer, MD · Principal Investigator

Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599

Recruiting
Emmie Cole · Contact
919-966-4432emmie_cole@med.unc.edu
Shetal Patel, MD · Principal Investigator

Atrium Health's Levine Cancer Institute

Charlotte, North Carolina, 28277

Recruiting
Jenna Gregory, MS, RN · Contact
Jenna.Gregory@atriumhealth.org
Kathryn F. Mileham, MD, FACP · Principal Investigator

Sanford Health- Bismarck

Bismarck, North Dakota, 58501

Recruiting
Peter Kurniali, MD · Contact
701-323-5741peter.kurniali@sanfordhealth.org
Peter Kurniali, MD · Principal Investigator

Sanford Health- Fargo

Fargo, North Dakota, 58122

Recruiting
Anu Gaba, MD · Contact
701-234-6161anu.gaba@sanfordhealth.org
Anu Gaba, MD · Principal Investigator

University of Cincinnati Medical Center

Cincinnati, Ohio, 45219

Recruiting
Kayla Webb, MSN, RN · Contact
513-584-0599webb2ka@ucmail.uc.edu
Davendra Sohal, MD · Principal Investigator

Kettering Health

Kettering, Ohio, 45429

Recruiting
Allison Dymacek, BSN, RN · Contact
937-395-8367allison.dymacek@ketteringhealth.org
Lex Leonhardt, DO · Principal Investigator

West Chester Hospital

West Chester, Ohio, 45069

Recruiting
Kayla Webb, MSN, RN · Contact
513-584-0599webb2ka@ucmail.uc.edu
Trisha Wise-Draper, MD · Principal Investigator

Providence Health & Services

Portland, Oregon, 97213

Recruiting
Isa Ngirailemesang · Contact
971-358-2056Isa.Ngirailemesang@providence.org
Evthokia Hobbs, MD · Principal Investigator

Lehigh Valley Hospital - Cedar Crest

Allentown, Pennsylvania, 18103

Recruiting
· Contact
734-712-3671MCRCwebsitecontactform@trinity-health.org
Maged Khalil, MD · Principal Investigator

Lehigh Valley Hospital- Muhlenberg

Bethlehem, Pennsylvania, 18017

Recruiting
· Contact
734-712-7251MCRCwebsitecontactform@trinity-health.org
Maged Khalil, MD · Principal Investigator

Pocono Medical Center

East Stroudsburg, Pennsylvania, 18301

Recruiting
· Contact
734-712-7251MCRCwebsitecontactform@trinity-health.org
Maged Khalil, MD · Principal Investigator

Lehigh Valley Hospital-Hazleton

Hazleton, Pennsylvania, 18201

Recruiting
· Contact
734-712-7251MCRCwebsitecontactform@trinity-health.org
Maged Khalil, MD · Principal Investigator

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111

Recruiting
Fathima S Sheriff · Contact
215-728-4094fathima.sheriff@fccc.edu
Margaret von Mehren, MD · Principal Investigator

SC Cancer Specialists at St. Joseph's/Candler Bluffton

Bluffton, South Carolina, 29910

Recruiting
Stephanie Smith, RN, MSN, OCN · Contact
912-819-5723smiths1@sjchs.org
Mark Taylor, MD · Principal Investigator

St. Joseph's/Candler Smith

Bluffton, South Carolina, 29910

Recruiting
Stephanie Smith, RN, MSN, OCN · Contact
912-819-5723smiths1@sjchs.org
Mark Taylor, MD · Principal Investigator

Summit Cancer Care at St. Josph's/Candler Bluffton

Bluffton, South Carolina, 29910

Recruiting
Stephanie Smith, RN, MSN, OCN · Contact
912-819-5723smiths1@sjchs.org
Mark Taylor, MD · Principal Investigator

South Carolina Cancer Specialists

Hilton Head Island, South Carolina, 29926

Recruiting
Stephanie Smith, RN, MSN, OCN · Contact
912-819-5723smiths1@sjchs.org
Mark Taylor, MD · Principal Investigator

Sanford Cancer Center Oncology Clinic and Pharmacy

Sioux Falls, South Dakota, 57104

Recruiting
Steven Powell, MD · Contact
605-328-8000steven.powell@sanfordhealth.org
Steven Powell, MD · Principal Investigator

Tennessee Oncology - Nashville / Sarah Cannon Research Institute

Nashville, Tennessee, 37203

Recruiting
Ethan Trull · Contact
615-329-7274Ethan.Trull@SarahCannon.com
Meredith McKean, MD, MPH · Principal Investigator

The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030

Recruiting
Kshipra Sharma, MPH, MS · Contact
713-745-8431Ksharma2@MDAnderson.org
Funda Meric-Bernstam, MD · Principal Investigator

Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center

Cedar City, Utah, 84720

Recruiting
Jake Kolu · Contact
435-705-1632Jake.Kolu@imail.org
Ramya Thota, MD · Principal Investigator
Derrick Haslem, MD · Principal Investigator

Intermountain Healthcare

Salt Lake City, Utah, 84107

Recruiting
Tracy Taylor · Contact
801-507-3953tracy.taylor@imail.org
Ramya Thota, M.D. · Principal Investigator
Derrick Haslem, M.D. · Principal Investigator

Dixie Regional Medical Center-River Road Campus

St. George, Utah, 84770

Recruiting
Jake Kolu · Contact
435-705-1632Jake.Kolu@imail.org
Ramya Thota, MD · Principal Investigator
Derrick Haslem, MD · Principal Investigator

Inova Schar Cancer Institute

Fairfax, Virginia, 22042

Recruiting
Roxana Comfort, CRC · Contact
571-472-0628roxana.comfort@inova.org
Timothy Cannon, MD · Principal Investigator

Northwest Medical Specialties

Bonney Lake, Washington, 98391

Recruiting
Jennifer Spokely · Contact
253-999-3701research@southsoundcare.org
Frank Senecal, MD · Principal Investigator

Northwest Medical Specialties

Federal Way, Washington, 98003

Recruiting
Jennifer Spokely · Contact
253-999-3701research@southsoundcare.org
Frank Senecal, MD · Principal Investigator

Northwest Medical Specialties

Gig Harbor, Washington, 98332

Recruiting
Jennifer Spokely · Contact
253-999-3701research@southsoundcare.org
Frank Senecal, MD · Principal Investigator

Northwest Medical Specialties

Olympia, Washington, 98502

Recruiting
Jennifer Spokely · Contact
253-999-3701research@southsoundcare.org
Frank Senecal, MD · Principal Investigator

Northwest Medical Specialties

Puyallup, Washington, 98373

Recruiting
Jennifer Spokely · Contact
253-999-3701reserch@southsoundcare.org
Frank Senecal, MD · Principal Investigator

Swedish Cancer Institute

Seattle, Washington, 98104

Recruiting
Sidney Ching · Contact
206-386-3142sidney.ching@swedish.org
Philip Gold, MD · Principal Investigator

Northwest Medical Specialties

Tacoma, Washington, 98405

Recruiting
Jennifer Spokely · Contact
253-999-3701reserch@southsoundcare.org
Frank Senecal, MD · Principal Investigator

Aurora Cancer Care - Burlington

Burlington, Wisconsin, 53105

Recruiting
Michelle Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

Aurora Health Care - Germantown Health Center

Germantown, Wisconsin, 53022

Recruiting
Michelle Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

Aurora Cancer Care - Grafton

Grafton, Wisconsin, 53024

Recruiting
Michelle Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

Aurora BayCare Medical Center

Green Bay, Wisconsin, 54311

Recruiting
Michelle Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

Aurora Cancer Care - Kenosha South

Kenosha, Wisconsin, 53142

Recruiting
Michelle Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

Aurora Bay Area Medical Center

Marinette, Wisconsin, 54143

Recruiting
Michelle Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

Aurora Cancer Care Milwaukee

Milwaukee, Wisconsin, 53209

Recruiting
Michelle M Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

Aurora St. Luke's Medical Center

Milwaukee, Wisconsin, 53215

Recruiting
Michelle M Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

Aurora Sinai Medical Center

Milwaukee, Wisconsin, 53223

Recruiting
Michelle Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

Aurora West Allis Medical Center

Milwaukee, Wisconsin, 53227

Recruiting
Michelle Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

Vince Lombardi Cancer Clinic - Oshkosh

Oshkosh, Wisconsin, 54904

Recruiting
Michelle Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

Aurora Cancer Care - Racine

Racine, Wisconsin, 53406

Recruiting
Michelle Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

Vince Lombardi Cancer Center

Sheboygan, Wisconsin, 53081

Recruiting
Michelle Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

Aurora Medical Center in Summit

Summit, Wisconsin, 53066

Recruiting
Michelle Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

Vince Lombardi Cancer Clinic - Two Rivers

Two Rivers, Wisconsin, 54241

Recruiting
Michelle Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

Aurora Cancer Care - Milwaukee West

Wauwatosa, Wisconsin, 53226

Recruiting
Michelle Toutloff, RN, CCRP · Contact
920-456-7880Michelle.Martin2@aah.org
Antony Ruggeri, MD · Principal Investigator

References

  • Cobain EF, Rothe M, Garrett-Mayer E, Cannon TL, Chan JK, Mileham KF, Adesunloye B, Calfa CJ, Alese OB, Butler KY, Dib EG, Pisick E, Bell M, Klute KA, Mehmi I, Meric-Bernstam F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Apr;10(4):e2501205. doi: 10.1200/PO-25-01205. Epub 2026 Apr 30.(PubMed)
  • Pisick E, Rothe M, Garrett-Mayer E, Srkalovic G, Chan JK, Calfa CJ, Leath CA 3rd, Marr AS, Gold PJ, Crane EK, Moyers JT, Yost Butler K, Gaba A, Thota R, Harnden KK, Alese OB, Jain A, Rueter J, Gill S, George TJ, Frimer M, Kayali F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Apr;10(4):e2500985. doi: 10.1200/PO-25-00985. Epub 2026 Apr 22.(PubMed)
  • Carrizosa DR, Rothe M, Mangat PK, Garrett-Mayer E, Behl D, Adesunloye B, Pisick E, Beekman KW, Dotan E, Akce M, Alese OB, Sahai V, Klute KA, Aragon-Ching JB, Cooper KA, Thota R, Meric-Bernstam F, Hosein PJ, Maestas EC, Moyers JT, Powell S, Zhao S, Hobbs E, Rueter J, Sohal DPS, Taylor MA, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Jan;10:e2500716. doi: 10.1200/PO-25-00716. Epub 2026 Jan 15.(PubMed)
  • Al Baghdadi T, Rothe M, Mangat PK, Garrett-Mayer E, Crysler OV, Mileham KF, Farrington LC, Adesunloye B, Dublis SA, Astsaturov I, Calfa CJ, Bleeker J, Khalil M, Thota R, Cannon TL, Alese OB, Gold PJ, Hafez N, Baron AD, Meric-Bernstam F, Hobbs E, Marr AS, Rueter J, Tawfik B, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2025 Oct;9:e2500649. doi: 10.1200/PO-25-00649. Epub 2025 Oct 16.(PubMed)
  • Mangat PK, Kirkwood MK, Hinshaw DC, Garrett-Mayer E, Schilsky RL. Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study. NPJ Precis Oncol. 2025 Jul 3;9(1):222. doi: 10.1038/s41698-025-00962-1.(PubMed)
  • Worden FP, Pisick E, Rothe M, Mangat PK, Garrett-Mayer E, Khalil MF, Carrizosa DR, Bauman JR, Leidner RS, Duvivier HL, Fu S, Park MS, Yost KJ, Calfa CJ, Marr AS, Balmanoukian AS, Behl D, Cannon TL, Nabell L, Powell SF, Thota R, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct;8:e2400477. doi: 10.1200/PO-24-00477. Epub 2024 Oct 16.(PubMed)
  • Schuetze S, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Calfa CJ, Farrington LC, Livingston MB, Wentzel K, Behl D, Kier Y, Marr AS, von Mehren M, Press JZ, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jul;8:e2400219. doi: 10.1200/PO.24.00219.(PubMed)
  • Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Brouse G, Chan J, Mehmi I, Khalil M, Duvivier HL, Gaba A, Leuva H, Thota R, Yost KJ, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jun;8:e2400026. doi: 10.1200/PO.24.00026.(PubMed)
  • Cannon TL, Rothe M, Mangat PK, Garrett-Mayer E, Chiu VK, Hwang J, Vijayvergia N, Alese OB, Dib EG, Duvivier HL, Klute KA, Sahai V, Ahn ER, Bedano P, Behl D, Sinclair S, Thota R, Urba WJ, Yang ES, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2024 Sep 20;42(27):3228-3237. doi: 10.1200/JCO.23.02078. Epub 2024 May 15.(PubMed)
  • Perez JK, Kleber J, Rothe M, Mangat P, Garrett-Mayer E, Schilsky RL. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar;8:e2300615. doi: 10.1200/PO.23.00615.(PubMed)
  • Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb;8:e2300513. doi: 10.1200/PO.23.00513.(PubMed)
  • Meric-Bernstam F, Rothe M, Mangat PK, Garrett-Mayer E, Gutierrez R, Ahn ER, Cannon TL, Powell S, Krauss JC, Reynolds CM, von Mehren M, Behl D, Calfa CJ, Duvivier HL, Kaplan HG, Livingston MB, Sharma MR, Urba WJ, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Sep;7:e2300385. doi: 10.1200/PO.23.00385.(PubMed)
  • Rohatgi N, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Pisick E, Alese OB, Reynolds CM, Thota R, Vaccaro GM, von Mehren M, Arend RC, Chiu VK, Duvivier HL, Gold PJ, Hack K, Marr AS, Winer A, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep;7:e2300279. doi: 10.1200/PO.23.00279.(PubMed)
  • Duvivier HL, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Al Baghdadi T, Alva AS, Dublis SA, Cannon TL, Calfa CJ, Li R, Behl D, Chiu VK, Gold PJ, Marr AS, Mileham KF, Powell SF, Rodon J, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2023 Nov 20;41(33):5140-5150. doi: 10.1200/JCO.23.00702. Epub 2023 Aug 10.(PubMed)
  • Mangat PK, Garrett-Mayer E, Perez JK, Schilsky RL. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. Clin Trials. 2023 Dec;20(6):699-707. doi: 10.1177/17407745231182013. Epub 2023 Jul 25.(PubMed)